Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
Public ClinicalTrials.gov record NCT04896697. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT04896697
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Xilio Development, Inc.
- Industry
- Enrollment
- 136 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Drug
- vilastobart (XTX101) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 12, 2021
- Primary completion
- Jun 11, 2026
- Completion
- Jun 11, 2026
- Last update posted
- May 4, 2026
2021 – 2026
United States locations
- U.S. sites
- 19
- U.S. states
- 9
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Hospital | Phoenix | Arizona | 85054 | — |
| City of Hope | Duarte | California | 91010 | — |
| California Cancer Associates for Research and Excellence, cCARE | Encinitas | California | 92024 | — |
| City of Hope-Lennar | Irvine | California | 92618 | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| California Cancer Associates for Research and Excellence, cCARE | San Marcos | California | 92069 | — |
| UCLA Hematology/Oncology- Santa Monica | Santa Monica | California | 90404 | — |
| City of Hope-Upland | Upland | California | 91786 | — |
| Mayo Clinic Hospital | Jacksonville | Florida | 32224 | — |
| Sarah Cannon Research Institute at Florida Cancer Specialists | Orlando | Florida | 32827 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Mayo Clinic Hospital | Rochester | Minnesota | 55905 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Carolina BioOncology Institute | Huntersville | North Carolina | 28078 | — |
| University of Pittsburgh Medical Center- Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Next Oncology | Austin | Texas | 78758 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | — |
| Tranquil Clinical Research | Webster | Texas | 77598 | — |
| NEXT Virginia | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04896697, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04896697 live on ClinicalTrials.gov.